H.R. 6593House115th Congress (2017-2019)In Committee

Medication Automated Quotation System, or MEDAQ, Act of 2018

Introduced July 26, 2018

AI-Generated Summary

Updated April 15, 2026 at 11:16 PM UTC

The MEDAQ Act of 2018 orders the Government Accountability Office’s Comptroller General to examine whether the United States could create an automated, searchable database that records the price each buyer pays for prescription drugs. The study must look at how to gather price data, protect privacy, cover costs, and whether new laws would be needed. It also asks whether such a system could help lower drug prices by increasing market transparency. A report of the findings must be delivered to Congress within about nine months.

Key Provisions

  • The Comptroller General, working with the FDA commissioner and the CMS administrator, must conduct a feasibility study for a Medication Automated Quotation system (MEDAQ).
  • The study must assess how to collect unit acquisition prices from all types of purchasers (distributors, retailers, insurers, consumers) without revealing personal information.
  • It must estimate the cost to build and maintain MEDAQ and identify any new laws or regulations needed to obtain the required data.
  • The study should explore linking MEDAQ with existing FDA National Drug Code (NDC) data and CMS’s National Average Drug Acquisition Cost (NADAC) system.
  • It must evaluate whether MEDAQ would likely reduce overall prescription drug prices by promoting competition and price transparency.
  • The Comptroller General must submit a report to Congress no later than 270 days after the Act’s enactment.

Legislative Activity

Stay on top of the latest movement without scrolling through every action

3 earlier actions
HouseCommittee Latest Action

Referred to the Subcommittee on Health.

July 27, 2018

View full timeline
HouseIntro Referral

Introduced in House

July 26, 2018

HouseIntro Referral

Sponsor introductory remarks on measure. (CR E1096-1097)

July 26, 2018

HouseIntro Referral

Referred to the House Committee on Energy and Commerce.

July 26, 2018

HouseCommittee

Referred to the Subcommittee on Health.

July 27, 2018

Bill Text

Latest available legislative text

Reading Mode
Latest
Introduced in HouseIssued July 26, 2018

I

115th CONGRESS

2d Session

H. R. 6593

IN THE HOUSE OF REPRESENTATIVES

July 26, 2018

Mr. Duncan of Tennessee introduced the following bill; which was referred to the Committee on Energy and Commerce

A BILL

To direct the Comptroller General of the United States to conduct a study on the feasibility of establishing and maintaining an automated and searchable system that tracks prescription drug prices in the United States, and for other purposes.

1.

Short title

This Act may be cited as the Medication Automated Quotation System, or MEDAQ, Act of 2018.

2.

Study on the feasibility of creating a system that tracks prescription drug costs

(a)

Study

The Comptroller General of the United States, in consultation with the Commissioner of Food and Drugs and the Administrator of CMS, shall conduct a study on the feasibility of establishing a medication automated quotation system.

(b)

Elements

The feasibility study required under subsection (a) shall include assessments of the following:

(1)

The feasibility of—

(A)

collecting or compiling data on the acquisition price per unit that any purchaser (including but not limited to a distributor, a retailer, a third-party payor, or ultimate consumer) pays for a prescription drug and the effect PBMs and other involved entities have on such prices; and

(B)

aggregating such data in a manner that does not reveal personally identifiable information.

(2)

The cost of procuring and maintaining a medication automated quotation system, or MEDAQ, based on the above data.

(3)

The need for new or additional laws, regulations, or policies to collect the data necessary for a medication automated quotation system to track and generate prescription drug pricing data in the United States.

(4)

The possibility of integrating or using the FDA's NDC system and CMS NADAC when creating the MEDAQ.

(5)

Integration of CMS NADAC when creating the MEDAQ and, not withstanding any other provision of this Act, shall not consider pharmacy reporting, collecting, or compiling requirements beyond or in addition to the requirements of CMS NADAC.

(6)

Whether the system described under subsection (a) is likely to be effective in reducing overall prescription drug prices by increasing competition and transparency in the drug industry.

(c)

Report

Not later than 270 days after the date of the enactment of this Act, the Comptroller General shall submit to Congress a report on the results of the study conducted under subsection (a).

(d)

Medication automated quotation system defined

The term medication automated quotation system or MEDAQ means an automated and searchable system that—

(1)

with respect to the United States (and with respect to each region thereof), tracks and generates data on the acquisition price per unit of any prescription drug that a purchaser pays for such unit of such drug;

(2)

produces reports in real time on average prices per unit and other data; and

(3)

is accessible to purchasers, who have paid a user fee, with limitations to ensure appropriate privacy but also transparency in price negotiations.